460 related articles for article (PubMed ID: 16096014)
21. Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax.
Garg H; Salcedo R; Trinchieri G; Blumenthal R
Cancer Gene Ther; 2010 Mar; 17(3):155-63. PubMed ID: 19816523
[TBL] [Abstract][Full Text] [Related]
22. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
23. [Comparative analysis of herpes simplex virus thymidine kinase gene expression potentiation via HIV-1 Tat-TAR-system and cancer-specific promoters in p53(+) and p53(-) cells].
Mingaleeva RN; Chernov IP; Kopantsev EP; Zavalova LL; Sass AV; Sverdlov ED
Mol Biol (Mosk); 2010; 44(3):507-14. PubMed ID: 20608175
[TBL] [Abstract][Full Text] [Related]
24. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication.
Kamizono J; Nagano S; Murofushi Y; Komiya S; Fujiwara H; Matsuishi T; Kosai K
Cancer Res; 2005 Jun; 65(12):5284-91. PubMed ID: 15958575
[TBL] [Abstract][Full Text] [Related]
25. Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53.
Mathai JP; Germain M; Marcellus RC; Shore GC
Oncogene; 2002 Apr; 21(16):2534-44. PubMed ID: 11971188
[TBL] [Abstract][Full Text] [Related]
26. Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer.
Ding Y; Wen Y; Spohn B; Wang L; Xia W; Kwong KY; Shao R; Li Z; Hortobagyi GN; Hung MC; Yan DH
Clin Cancer Res; 2002 Oct; 8(10):3290-7. PubMed ID: 12374701
[TBL] [Abstract][Full Text] [Related]
27. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.
Ulasov IV; Rivera AA; Sonabend AM; Rivera LB; Wang M; Zhu ZB; Lesniak MS
Cancer Biol Ther; 2007 May; 6(5):679-85. PubMed ID: 17404502
[TBL] [Abstract][Full Text] [Related]
28. Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB.
Zhang Y; Yu J; Unni E; Shao TC; Nan B; Snabboon T; Kasper S; Andriani F; Denner L; Marcelli M
Hum Gene Ther; 2002 Nov; 13(17):2051-64. PubMed ID: 12490000
[TBL] [Abstract][Full Text] [Related]
29. Suppression activity of pro-apoptotic gene products in cancer cells, a potential application for cancer gene therapy.
Lin J; Page C; Jin X; Sethi AO; Patel R; Nunez G
Anticancer Res; 2001; 21(2A):831-9. PubMed ID: 11396172
[TBL] [Abstract][Full Text] [Related]
30. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
[TBL] [Abstract][Full Text] [Related]
31. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy.
Murofushi Y; Nagano S; Kamizono J; Takahashi T; Fujiwara H; Komiya S; Matsuishi T; Kosai K
Int J Oncol; 2006 Sep; 29(3):681-8. PubMed ID: 16865285
[TBL] [Abstract][Full Text] [Related]
32. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574
[TBL] [Abstract][Full Text] [Related]
33. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
Xie X; Hsu JL; Choi MG; Xia W; Yamaguchi H; Chen CT; Trinh BQ; Lu Z; Ueno NT; Wolf JK; Bast RC; Hung MC
Mol Cancer Ther; 2009 Aug; 8(8):2375-82. PubMed ID: 19671744
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional regulatory regions of the survivin gene activate an exogenous suicide gene in human tumors and enhance the sensitivity to a prodrug.
Kawamura K; Yu L; Tomizawa M; Shimozato O; Ma G; Li Q; Sato A; Yang Y; Suzuki T; Abdel-Aziz NM; Tagawa M
Anticancer Res; 2007; 27(1A):89-93. PubMed ID: 17352220
[TBL] [Abstract][Full Text] [Related]
35. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
Gu J; Kagawa S; Takakura M; Kyo S; Inoue M; Roth JA; Fang B
Cancer Res; 2000 Oct; 60(19):5359-64. PubMed ID: 11034071
[TBL] [Abstract][Full Text] [Related]
36. Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression.
Woraratanadharm J; Rubinchik S; Yu H; Dong JY
BMC Biotechnol; 2007 Feb; 7():9. PubMed ID: 17295927
[TBL] [Abstract][Full Text] [Related]
37. Apoptotic genes in cancer therapy.
Opalka B; Dickopp A; Kirch HC
Cells Tissues Organs; 2002; 172(2):126-32. PubMed ID: 12426489
[TBL] [Abstract][Full Text] [Related]
38. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
39. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
40. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription.
Endoh T; Tsuji N; Asanuma K; Yagihashi A; Watanabe N
Exp Cell Res; 2005 May; 305(2):300-11. PubMed ID: 15817155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
